Buscar (Noticias)

Claudin 18.2 Targeted Therapy Market Research 2026: Astellas' Zolbetuximab Leads Gastric Cancer Progress, While Servier Pharmaceuticals And Others Expand ADC And CAR-T Strategies - Forecasts To 2030

health top

(MENAFN - GlobeNewsWire - Nasdaq) The Claudin18.2 targeted therapy market offers significant opportunities in treating advanced cancers such as gastric and pancreatic. With one approved therapy and ...
2026-02-10 04:16:13